BeiHai Biotech's First-in-Class Docetaxel Reformulation BEIZRAY® Secures $25M Upfront in Landmark U.S. Licensing Deal with Zydus

On February 18, Zhuhai Beihai Biotechnology Co., Ltd. (hereinafter referred to as "Beihai Biotech") announced that it had entered into a strategic partnership with Zydus Lifesciences, granting the latter exclusive commercialization rights for its improved novel drug docetaxel, BEIZRAY (BH009), in the U.S. market.

Under the terms of the agreement, Beihai Biotech will be responsible for the manufacturing and supply of BEIZRAY, while Zydus Pharmaceuticals, the U.S. subsidiary of Zydus, will handle the commercialization of the product in the United States. Beihai Biotech will receive upfront payments totaling $25 million—comprising $15 million payable upon signing of the agreement and $10 million payable after the first product delivery (note: the upfront payments are equivalent to approximately RMB 180 million)—as well as multiple sales milestone payments and high double-digit profit sharing.

BEIZRAY is an improved new drug based on docetaxel, independently developed by Beihai Biotech. It is also the first improved new drug with significant clinical advantages to be clinically validated in the nearly 30 years since docetaxel was launched.

Docetaxel is a widely used antineoplastic agent, primarily indicated for the treatment of various solid tumors, including breast cancer, non-small cell lung cancer, gastric cancer, prostate cancer, and squamous cell carcinoma of the head and neck. Although novel oncology therapies such as bispecific antibodies (bsAbs), antibody-drug conjugates (ADCs), and cell therapies are emerging, they still face numerous challenges regarding clinical adoption, cost-effectiveness, patient acceptance, and therapeutic efficacy in certain specific tumor types. Consequently, traditional chemotherapy agents like docetaxel continue to maintain a solid core position in cancer treatment.

According to IQVIA MAT data as of December 2024, the annual consumption of docetaxel injection in the U.S. market is approximately 531,000 vials. As a cornerstone drug in oncology treatment, docetaxel has achieved global annual sales exceeding $2 billion since its launch in 1996.

However, the clinical application of docetaxel is not without issues; its significant efficacy is accompanied by adverse reactions that cannot be overlooked, particularly allergic and hypersensitivity reactions. The primary cause of these reactions is the poor water solubility of docetaxel, which necessitates the addition of polysorbate 80 (Tween 80) and anhydrous ethanol as co-solvents. Tween 80, a polyol-type nonionic surfactant, may trigger allergic reactions and hemolytic responses.

A study published in the Journal of the European Academy of Dermatology and Venereology showed that 77% of patients experienced allergic reactions after injection of solutions containing polysorbate 80 in multiple human skin prick tests, and the content of polysorbate 80 in the formulation was positively correlated with the incidence and severity of allergic reactions. Therefore, the U.S. Food and Drug Administration (FDA) has issued a black box warning for all docetaxel products containing polysorbate 80 to alert users to the risks associated with their use.

Given the critical importance of clinical medication safety for oncology drugs, pharmaceutical companies worldwide have been striving since docetaxel’s market launch in 1996 to reduce its toxic side effects, enhance efficacy, and significantly improve clinical safety by optimizing drug formulations and delivery methods. However, these efforts have yet to fundamentally resolve the issue. Prior to BEIZRAY, no innovative docetaxel products free of polysorbate 80 had been approved in major global markets.

BEIZRAY, leveraging innovative formulation technology, has become the world first improved docetaxel drug free of Tween 80 and cyclodextrin. Clinical data show that this drug reduces the incidence of hematologic toxicity by 30%–50% and lowers the risk of severe allergic reactions by 80%.

Notably, BEIZRAY secured U.S. FDA marketing approval just five years after its project initiation in 2019, demonstrating Beihai Biotech’s exceptional R&D capabilities and efficient execution as an innovative pharmaceutical company.

It is reported that following FDA approval in October 2024, BEIZRAY rapidly expanded its indications to cover five major solid tumor types, including breast cancer, non-small cell lung cancer, prostate cancer, gastric cancer, and head and neck squamous cell carcinoma, becoming the first internationally certified breakthrough product in the field of docetaxel modification in nearly three decades.

This collaboration not only marks a significant milestone in Beihai Biotech’s accumulated expertise in anti-tumor drug development and its global strategic blueprint, but also underscores the rising prominence of Chinese biopharmaceutical enterprises on the global stage.

Beihai Biotech is an innovative biopharmaceutical company dedicated to developing novel oncology drugs that address unmet clinical needs with a patient-centric approach. The company possesses a molecular targeted delivery technology platform and a PDC (Peptide-Drug Conjugate) conjugation technology platform. It has established a pipeline of more than 10 differentiated innovative drug candidates, with multiple new drug projects having entered clinical stages. To date, it has obtained 11 Investigational New Drug (IND) approvals for clinical trials in China and the United States.

Zydus is a multinational pharmaceutical company headquartered in India. Founded in 1952, it stands as one of the leading global pharmaceutical enterprises. With annual sales exceeding USD 2 billion, the Group employs over 27,000 people worldwide and operates in more than 50 countries. Focusing on therapeutic areas such as oncology and metabolic diseases, Zydus maintains over 30 modern manufacturing facilities globally. The company is dedicated to research and development, production, and commercialization in the healthcare sector, with a mission to develop high-quality medical solutions and drive groundbreaking advancements in life sciences. Zydus is committed to improving human health through pioneering scientific achievements.

BEIZRAY is the first improved new drug in China to successfully achieve licensed export to the United States in recent years. This international licensing agreement also marks a critical step forward in Beihai Biotech’s internationalization strategy.

Notably, the development and regulatory filing of improved new drugs is a comprehensive issue involving technology, market, regulations, clinical aspects, and more. From project feasibility analysis, feasibility studies, Pre-IND meetings, non-clinical research, clinical trials, to NDA submission and approval, it is clearly a long-term systematic engineering process.

Beihai Biotech’s development strategy for BEIZRAY clearly reflects its ambitious global vision. By launching its first approved novel drug in the U.S. market, the company aims to swiftly gain international recognition, paving a solid path for future expansion into other global markets. This approach also provides an ideal platform to showcase its technological prowess on the international stage, underscoring its leading position in innovative drug research and development.

The successful global launch of BEIZRAY marks the entry of China’s improved new drugs into mainstream international markets, and further signifies that Beihai Biotech’s drug R&D capabilities and product quality have reached the highest international standards. Through its commercialization progress in the U.S. market, Beihai Biotech has accumulated valuable international experience, laying a solid foundation for its role as a pioneer among Chinese innovative drug companies going global.

Leveraging their short development cycles and high success rates, improved new drugs are emerging as a new arena for Chinese pharmaceutical companies to compete globally. With continuous breakthroughs by innovative players such as Beihai Biotech, China’s biopharmaceutical industry is poised to achieve overtaking on the bend in the field of advanced drug formulations.

References:
Securing Guangdong’s First! BEIZRAY Receives U.S. FDA Approval for Market Launch, Marking Another Step Forward in Beihai Biotech’s Globalization Strategy – VCBeat